PMID int64 27.8M 36.2M | Title/Abstract stringlengths 7 10.7k | MeshTerms stringlengths 7 104 | SemanticTypes stringlengths 4 84 |
|---|---|---|---|
34,661,567 | duct doubl resin cast follow micro comput tomographi liver analysi liver biggest intern organ human mice high auto fluoresc present signific challeng assess three dimension architectur organ whole organ level liver architectur character multipl branch lumen structur fill resin includ vascular biliari tree establish high stereotyp pattern otherwis hepatocyt rich parenchyma protocol describ pipelin perform doubl resin cast micro comput tomographi duct duct entail inject portal vein common bile duct two differ radiopaqu synthet resin follow tissu fixat qualiti control clear one lobe entir liver optic clear agent allow pre screen suitabl inject sampl second part duct pipelin lobe whole liver use micro comput tomographi microct scan semi autom segment render portal venous biliari network microct result coordin data two resin allow qualit well quantit analysi two system spatial relationship duct appli postnat adult mous liver extend tubular network exampl vascular network airway lung | D001659;D008099 | T023 |
34,661,566 | effici scalabl generat human ventral midbrain astrocyt human induc pluripot stem cell parkinson diseas progress dysfunct degener dopamin neuron ventral midbrain caus life chang symptom neuron degener divers caus parkinson includ non cell autonom mechan mediat astrocyt throughout cns astrocyt essenti neuron surviv function maintain metabol homeostasi neural environ astrocyt interact immun cell cns microglia modul neuroinflamm observ earliest stage parkinson direct impact progress patholog diseas chronic neuroinflammatori element includ parkinson astrocyt acquir neurotox phenotyp thus enhanc neurodegener consequ astrocyt potenti therapeut target slow halt diseas requir deeper understand properti role parkinson accur model human ventral midbrain astrocyt vitro studi therefor urgent requir develop protocol generat high puriti cultur ventral midbrain specif astrocyt vmastro hipsc use parkinson research vmastro routin produc multipl hipsc line express specif astrocyt ventral midbrain marker protocol scalabl thus suitabl high throughput applic includ drug screen crucial hipsc deriv vmastro demonstr immunomodulatori characterist typic vivo counterpart enabl mechanist studi neuroinflammatori signal parkinson | D057026 | T025 |
34,661,563 | characterist asian american breast cancer survivor retain month technolog base intervent technolog base intervent program known effect approach social exclud group racialethn minor includ specif popul howev retent particip technolog base intervent studi far complic challeng compar convent studi target racialethn minor | D001943;D000073116 | T191;T101;T201 |
34,661,561 | unexpect retrostern goiter interpret hyperfunct metastasi posttherapeut spectct present year old man underw total thyroidectomi radic right neck dissect due papillari thyroid cancer refer treatment patient subclin hypothyroid remark stimul tg level week l thyroxin withdraw treatment indic hyperfunct metastasi posttherapeut whole bodi scan combin spectct perform day administr reveal elev uptak mass cervicothorac region surpris mass histolog confirm retrostern goiter | D006042;D013964 | T191;T047 |
34,661,560 | subdiaphragmat lymph node uptak f fdg petct covid vaccin thigh sinc worldwid covid vaccin f fdg uptak reactiv axillari lymph node frequent observ petct studi describ patient breast cancer underw f fdg petct day receiv covid vaccin right thigh f fdg uptak observ nonenlarg right side inguin iliac para aortic lymph node thigh use altern site covid vaccin inject case lymphedema arm adequ axillari stage patient breast cancer physician awar f fdg uptak pattern | D000086382;D000086663 | T047;T200;T067 |
34,661,559 | clinic manag end stage renal diseas patient dialysi receiv radioact iodin treatment radioact iodin rai use treat thyroid cancer patient clear paradigm patient end stage renal diseas esrd patient pose sever challeng undergo rai treatment primarili due lack renal clearanc retrospect report experi rai treatment cohort patient esrd provid set recommend aspect need adjust dose activ balanc schedul rai therapi dialysi radiat safeti precaut | D007676;D013964 | T191;T047 |
34,661,558 | f cholin pet detect third ventricl craniopharyngioma craniopharyngioma rare tumor low histolog malign world health organ grade sellar suprasellar region brain report case third ventricular craniopharyngioma detect use f cholin petct year old man mri brain reveal intens gadolinium enhanc focus area histolog reveal characterist papillari craniopharyngioma find suggest craniopharyngioma includ differenti diagnosi f cholin avid brain lesion | D003397;D010911;D020542 | T191;T030 |
34,661,557 | f fdg versus ga fapi petct visual primari hepat extranod margin zone lymphoma mucosa associ lymphoid tissu preval primari hepat mucosa associ lymphoid tissu lymphoma extrem low case present f fdg ga fapi petct find year old man patholog confirm primari hepat extranod margin zone lymphoma mucosa associ lymphoid tissu ga fapi petct show better tumor background ratio f fdg petct hepat lesion littl ga fapi uptak liver parenchyma case indic ga fapi petct may altern method evalu hepat involv lymphoma especi non fdg avid lymphoma | D018442;D000072078 | T191;T060 |
34,661,556 | diagnost test accuraci f fdg pet petct character histolog type thymic epitheli tumor meta analysi studi investig diagnost accuraci f fdg pet petct character histolog type thymic epitheli tumor tet systemat review meta analysi | D009375;D013953 | T191 |
34,661,555 | fdg petct imag solitari rib hamartoma hamartoma rib rare adult herein report year old woman complain chest pain month fdg petct reveal focal osteolyt bone destruct right th rib elev fdg uptak postop patholog support diagnosi hamartoma case show hamartoma consid differenti diagnosi solitari osteolyt bone destruct rib intens fdg uptak | D019788;D006222 | T130;T191;T109 |
34,661,554 | intracavern schwannoma character f fdg ga dotatoc f cholin pet report case year old man histori prostat cancer whose left intracavern lesion success character pet perform success differ tracer poor character tumor initi discov mri conduct investig acut diplopia slowli grow follow f fdg pet lesion show signific uptak extracrani lesion found increas ga dotatoc uptak final tumor display high f cholin uptak extracrani lesion reveal tracer diagnosi schwannoma without malign criterion proven biopsi | D019788;D009442 | T130;T191;T109 |
34,661,553 | use antifibrinolyt pediatr life threaten hemorrhag prospect observ multicent studi assess impact antifibrinolyt children life threaten hemorrhag | D000933;D014148 | T121;T109 |
34,661,550 | manag treatment patient obstruct sleep apnea use intellig monitor system base machin learn aim improv continu posit airway pressur treatment complianc random control trial continu posit airway pressur cpap effect treatment obstruct sleep apnea osa treatment complianc often unsatisfactori | D045422;D020181 | T047;T061 |
34,661,548 | augment realiti guidelin present medicin random crossov simul trial technic assist decis make guidelin provid instruct diagnost therapi modern medicin various mobil devic use repres potenti complex decis tree exampl time critic decis triag case mass casualti incid | D000081411;D054527 | T051;T170;T098 |
34,661,544 | human organ technolog perspect patient experi chat base autom medic histori take servic primari health care interview studi among primari care patient use e visit health care progress rapid worldwid date studi advantag disadvantag e consult form chat servic inquiri primari care focus perspect health care profession hcps rather end user patient | D006282;D011320 | T097;T058 |
34,661,543 | psychometr properti internet game disord scale short form igd sf systemat review internet game disord scale short form igd sf among best regard psychometr properti therefor clinic psychologist like guid use igd sf want assess screen disord game practic howev inform especi psychometr evid concern igd sf fulli examin summar | D000082424;D018910 | T048;T073 |
34,661,539 | examin trend onlin health inform seek behavior chronic obstruct pulmonari diseas singapor analysi data googl trend global burden diseas studi chronic obstruct pulmonari diseas copd third lead caus death global time health care seek imper prevent earli detect manag onlin health inform seek behavior ohisb increas popular due widespread internet connect littl known ohisb copd chang comparison copd diseas burden particular countri specif level | D057226;D029424 | T047;T055 |
34,661,530 | earli predict hospit death covid patient machin learn model base age blood analys chest x ray score earli warn model predict hospit mortal admiss covid patient emerg depart ed develop valid use machin learn model total patient enrol march decemb includ patient first wave patient second wave covid outbreak itali first wave patient divid two group patient use train model valid patient second wave use test model age blood analyt brescia chest x ray score variabl process use random forest classif algorithm build valid model receiv oper characterist roc analysi use assess model perform web base death risk calcul implement integr within laboratori inform system hospit final score construct age power predictor blood analyt strongest predictor lactat dehydrogenas dimer neutrophillymphocyt ratio c reactiv protein lymphocyt ferritin std monocyt brescia chest x ray score https bdbiomedshinyappsiocovidscor area roc curv obtain three group train valid test respect model predict hospit mortal basi data obtain short time direct ed admiss function web base calcul provid risk score easi interpret use triag process support decis patient alloc | D017052;D000069550 | T080;T066 |
34,661,524 | collagen polar promot epitheli elong stimul locoregion cell prolifer epitheli network common generat process multicellular aggreg elong branch focus understand cellular mechan elong use organotyp cultur system model mammari epitheli anlag isotrop cell aggreg broke symmetri slowli elong transplant collagen gel elong region aggreg display enhanc cell prolifer necessari elong occur strike locoregion increas cell prolifer occur collagen fibril reorgan bundl polar elong aggreg appli extern stretch cell independ way reorgan extracellular matrix found collagen polar stimul region cell prolifer precipit symmetri break elong requir integrin erk signal propos collagen polar support epitheli anlagen elong stimul locoregion cell prolifer could provid long last structur memori initi axi generat anlag break symmetri | D049109 | T043 |
34,661,523 | mobil app usag among dermatolog resid america mobil applic app grow part medicin last decad cross section onlin survey studi role app dermatolog resid train demograph result respons rate suggest studi sampl repres target popul dermatolog resid america survey highlight increas role app dermatolog resid train differ prioriti among differ year resid differ inform util sex knowledg help guid standard qualiti assur formal integr medic mobil app tradit dermatolog teach | D003880;D007396;D063731 | T091;T065;T097;T170 |
34,661,519 | herc e ligas mediat isgyl hepat b virus x protein promot viral replic ubiquitin ubiquitin like protein modif play import role modul function viral protein mani virus demonstr hepat b virus hbv x protein hbx modifi isg type ifn induc ubiquitin like protein modif call isgyl immunoblot analys reveal hbx protein deriv four differ hbv genotyp accept isgyl cultur cell site direct mutagenesi reveal three lysin residu k k k hbx protein well conserv among hbv genotyp involv accept isgyl use express plasmid encod three known e ligas involv isgyl differ substrat found herc function e ligas hbx isgyl treatment type type iii ifn result limit suppress hbv replic hep tet cell cell treat ifn silenc isg result mark reduct hbv replic hep tet cell suggest role isg resist ifn contrast silenc usp isg de conjug enzym increas hbv replic hep tet cell taken togeth result suggest herc mediat isgyl hbx protein confer pro viral function hbv replic particip resist ifn mediat antivir activ | D014779 | T043 |
34,661,518 | genom methylom analysi phylogenet novel campylobact coli cluster c jejuni introgress intrigu recent discoveri campylobact coli strain especi clade possess mosaic c coli c jejuni allel ii demonstr mix multilocus sequenc type mlsts iii undergon genom wide introgress led specul two speci may involv acceler rate horizont gene transfer progress lead merg speci process coin despeci mlst base neighbour join tree number c coli c jejuni isol differ clade three promin campylobact isol form seem separ cluster besid previous describ c coli c jejuni clade light suspect ongo genet introgress c coli c jejuni speci cluster campylobact isol propos present one hybrid clonal complex despeci process genus specif dna methyl well restrict modif system known involv select uptak extern dna role genet introgress remain investig studi phylogeni dna methyl putat c coli c jejuni hybrid strain explor genom mosaic structur caus c jejuni introgress demonstr basic phenotyp assay use character isol genom three hybrid campylobact strain sequenc use pacbio smrt sequenc follow methylom analysi restrict modif finder genom analysi parsnp smash blast addit strain phenotyp character respect growth behaviour motil eukaryot cell invas adhes autoagglutin biofilm format water surviv abil analys show three hybrid campylobact strain clade c coli strain acquir genom c jejuni c jejuni genom segment acquir distribut entir genom form coher cluster gene origin c jejuni involv chemotaxi motil membran transport cell signal resist toxic compound bile acid interspeci gene transfer c jejuni contribut genom three c coli isol initi despeci c jejuni c coli base function annot gene origin c jejuni enabl adapt three strain intra intestin habitat transfer fuse type ii restrict modif system recogn caynnnnnctcgagnnnnnrtg motif seem key recombin c jejuni genet materi c coli genom | D000081122;D016680;D010802 | T062;T028;T078 |
34,661,515 | character microbi communiti rumen larg intestin lactat creol goat graze arid plant communiti arid plant communiti provid variabl diet affect digest microbi communiti free forag rumin thus use next generat sequenc rdna character microbi communiti rumen regurgit digesta larg intestin faec diet composit lactat creol goat five flock graze nativ plant communiti sonoran desert raini season bacteri communiti rumen larg intestin five flock similar alpha divers chao shannon simpson indic howev bacteri communiti composit differ bacteri communiti domin proteobacteria rumen transit communiti domin firmicut larg intestin bacteri communiti rumen similar across flock similar occur larg intestin communiti archaea minimum presenc goat digest tract detect phylum basidiomycota ascomycota apicomplexa main fungi protozoa analys suggest differ diet composit forb grass compos bulk plant rumen forb shrub faec therefor lactat goat consum differ diet sonoran desert raini season share similar core bacteri communiti rumen anoth larg intestin present low archaeal communiti | D000069196 | T007;T001 |
34,661,514 | quantum mechan virtual screen molecular dock molecular dynam adm antimicrobi activ studi new indol hydrazon deriv potent agent e faecali studi new seri indol carbaldehyd hydrazon deriv compound design synthes antimicrobi activ determin microdilut method vitro cytotox effect bea b cell line investig mtt assay activ result examin show promis activ e faecali mic gml compar ampicillin gentamicin vancomycin although antimicrobi activ indol deriv general weaker standard drug compound show cytotox activ mcf bea b cell line molecular dock studi perform differ protein understand mechan good antimicrobi action e faecali conclud compound interact fabh enough protein structur molecular dynam simul perform investig protein ligand stabil activ compound e faecali rmsd valu vari nm md simul apoprotein peak nm begin simul stabil nm theoret adm profil compound calcul found compli lipinski limit rule addit theoret quantum paramet homo lumo compound mep analysi geometr optim analysi calcul use g p base set dftblyp theori result visual communic ramaswami h sarma | D000890;D000970 | T121;T109 |
34,661,513 | relationship menopaus symptom perceiv stress covid pandem studi aim examin relationship menopaus symptom perceiv stress middl age women covid pandem cross section studi data collect onlin middl age women use person inform form menopaus rate scale mrs perceiv stress scale pss posit correl found total mrs score total pss score covid pandem usual restrict access healthcar visit covid pandem creat urgent need implement specif menopaus program promot psycholog health middl age women reduc stress similar crise | D000086382 | T047;T067 |
34,661,511 | identif prognost chemoresist relat gene signatur associ immun microenviron breast cancer breast cancer common form cancer among women global chemoresist major challeng diseas treatment associ poor prognosi studi formul identifi reliabl prognost biosignatur capabl predict surviv patient chemoresist breast cancer crbc evalu associ tumor immun microenviron seri protein protein interact weight correl network analys gene signific associ breast cancer chemoresist identifi moreov univari cox regress lasso penal cox regress analys employ generat prognost model prognost util model assess use time depend receiv oper characterist roc kaplan meier surviv curv final cibersort estim algorithm addit leverag assess relationship tumor immun microenviron patient prognost signatur overal multigen prognost biosignatur capabl predict crbc patient risk success develop base bioinformat analysi vitro experi biosignatur abl stratifi crbc patient high low risk subgroup roc curv also reveal biosignatur achiev high diagnost effici multivari regress analys indic risk signatur independ risk factor link crbc patient outcom addit signatur associ infiltr tumor microenviron multipl immun cell type conclus chemoresist associ prognost gene signatur develop herein abl effect evalu prognosi crbc patient reflect overal composit tumor immun microenviron | D019008 | T042;T038 |
34,661,509 | relationship rotat shift work white blood cell count white blood cell differenti count obes metabol syndrom nurs studi investig relationship work rotat shift white blood cell wbc count wbc differenti count dc obes metabol syndrom nurs sampl obtain total nurs receiv health checkup larg teach hospit taiwan among nurs work rotat shift remain nurs work fix daytim shift use binari logist regress identifi risk factor obes metabol syndrom result indic nurs work rotat shift signific higher wbc count work fix daytim shift wbc count independ factor relat over larg waist circumfer over high bodi mass index bmi nurs everi l increas wbc count risk waist circumfer exceed cm cm respect male femal nurs increas everi l increas wbc count risk bmi kgm nurs increas similar wbc count work type independ factor influenc metabol syndrom nurs everi l increas wbc count risk metabol syndrom occur nurs increas nurs work rotat shift time greater risk metabol syndrom work fix daytim shift mean age particip year old approxim particip metabol syndrom among nurs found high wbc correl over larg waist circumfer over high bmi furthermor nurs work rotat shift may greater risk metabol syndrom work fix daytim shift increas wbc also associ occurr metabol syndrom | D024821;D009726;D000073577 | T097;T047;T057 |
34,661,508 | systemat review meta analysi risk score predict clinic outcom patient acut varic bleed acut varic bleed avb life threaten condit need risk stratif guid clinic treatment risk system could reflect prognosi accur remain controversi aim conduct meta analysi predict valu gbs aim rockal clinic rockal score full rockal score ctp meld | D004932;D006471 | T046;T047;T020 |
34,661,507 | rituximab cyclophosphamid doxorubicin vincristin prednisolon r chop therapi increas carotid intima media thick plaqu score von willebrand factor activ elev patient malign lymphoma increas risk atherosclerosi note cancer survivor howev studi focus risk atherosclerosi patient treat chemotherapi scarc therefor evalu patient receiv rituximab cyclophosphamid doxorubicin vincristin prednisolon r chop therapi b cell malign lymphoma analys chang atherosclerosi treatment cours plasma level von willebrand factor vwf activ evalu carotid ultrasonographi perform baselin final treatment throughout follow period plasma vwf level show signific transient increas approxim mean carotid intima media thick imt plaqu score ps signific increas week observ mean imt mm ps p studi suggest r chop therapi promot atherosclerosi | D050197;D016393 | T191;T047;T046 |
34,661,504 | assess work condit medic facil due nois factor relat work environ eg inadequ light excess nois poor condit premis contribut neglect work medic personnel also caus health effect bodi articl present result assess work condit workplac select medic facil poland assess base survey result survey conduct mean questionnair among physician nurs diagnost laboratori staff averag grade nois annoy workplac scale therefor nois assess slight inconveni | D009622;D017132 | T082;T069;T067 |
34,661,503 | children percept factor influenc physic activ focus group studi primari school children establish healthi lifestyl behaviour primari school children import behaviour like track adulthood studi aim explor factor influenc physic activ pa primari school children perspect | D015444;D012574 | T092;T061;T073;T056 |
34,661,498 | preval prognosi hyponatraemia non hodgkin lymphoma associ hemophagocyt lymphohistiocytosi non hodgkin lymphoma associ hemophagocyt lymphohistiocytosi nhl hlh adult secondari hlh common univers high lethal critic disord hyponatraemia common electrolyt disord critic ill set act negat prognost factor aim studi evalu prognost role hyponatraemia among patient nhl hlh result show patient hyponatraemia median follow rang day cumul death hyponatraemia group normonatremia group adjust confound multivari analysi reveal hyponatraemia independ prognost factor os hr ci p restrict cubic spline confirm linear posit associ serum sodium risk mortal hyponatraemia relat frequent nhl hlh readili avail biomark clinic routin promis prognost predictor nhl hlh | D007010;D051359;D008228 | T191;T047 |
34,661,497 | waist circumfer hip circumfer arm span waist hip ratio high risk polycyst ovarian syndrom polycyst ovarian syndrom reproduct problem women high preval case accompani obes condit obes condit seen size waist circumfer hip circumfer arm span waist hip ratio studi aim find risk factor waist circumfer size hip circumfer arm span waist hip ratio polycyst ovarian syndrom | D011085 | T047 |
34,661,495 | mind base psychoeduc schizophrenia spectrum disord qualit analysi particip experi mind base psychoeduc program mbpp propos new approach improv overal outcom individu schizophrenia spectrum disord howev date limit studi examin particip experi mbpp schizophrenia | D064866;D012559 | T048;T041 |
34,661,492 | clinic pharmaceut screen critic situat radioiodin therapi manag servic radioiodin therapi use differenti thyroid carcinoma requir extens evalu ensur effect safeti therefor necessari evalu health problem medic use pre radioiodin therapi period comprehens medic managementservic serv screen tool context present studi aim describ critic clinic situat identifi initi assess comprehens medic manag servic offer differenti thyroid carcinoma patient pre radioiodin therapi pharmaceut intervent perform solv descript studi regard initi ten month comprehens medic manag servic carri larg oncolog hospit rio de janeiro brazil descript analysi use describ critic clinic situat identifi well correspond drug therapi problem type accept outcom pharmaceut intervent perform solv thirti patient averag year medic evalu five critic clinic situat identifi correspond drug therapi problem two need addit drug therapi n drug therapi problem four dosag low n pharmaceut intervent accept comprehens medic manag servic provis pre radioiodin therapi feasibl repres import screen strategi | D004364;D010604;D010607 | T091;T093;T121;T057 |
34,661,490 | vitro hemocompat investig develop low flow centrifug blood pump less platelet clog low flow blood pump rate lmin emerg new medic applic hemofiltr acut use pump platelet adhes aggreg care consid clog risk filter part find accept hemocompat appli low flow centrifug blood pump design platelet aggreg index clog micromesh filter hemolysi index investig use low flow blood pump design hemofiltr use conduct circul test vitro use fresh porcin blood two centrifug pump differ impel inlet shape negat log platelet aggreg threshold index nl pati reflect abil residu platelet aggreg flow rate measur reflux min normal index hemolysi nih g min calcul addit blood cell clog reflux observ micromesh filter sem adhes rate calcul result show platelet clog micromesh filter occur averag nl pati greater averag nih g min greater contrast platelet clog micromesh suppress nl pati less nih g min less valu might use accept hemocompat low flow centrifug blood pump suppress platelet clog hemofiltr pump | D001792;D006353 | T025;T074 |
34,661,489 | aplast anemia secondari tyrosin kinas inhibitor therapi patient chronic myeloid leukemia nilotinib second generat tyrosin kinas inhibitor signific efficaci patient chronic myeloid leukemia resist intoler imatinib aplast anemia induc tyrosin kinas inhibitor uncommon complic | D000741;D015464 | T191;T047 |
34,661,488 | evalu train program prevent violent radic health educ profession articl present preliminari evalu train session promot system approach violent radic vr offer first line health educ profession quebec describ rational content train program general principl implement modal mix method evalu indic particip felt train increas level confid deal vr work appear train also shift particip attitud signific four item decreas worri extent vr young peopl quebec belief vr automat report polic think islam favor vr assumpt enhanc secur measur would deterr effect vr conclus discuss challeng associ violent radic train program emphas delic ethic polit question relat provis train social divis topic | D007514 | T098;T078 |
34,661,487 | semiparametr mix effect model censor longitudin data longitudin studi involv laboratori base outcom repeat measur censor due assay detect limit linear mix effect lmes model power tool model relationship respons variabl covari longitudin studi howev linear parametr form linear mix effect model often restrict character complex relationship respons variabl covari general robust model tool nonparametr semiparametr regress model becom increas popular last decad articl use semiparametr mix model analyz censor longitudin data irregular observ repeat measur propos model extend censor linear mix effect model provid flexibl model scheme allow time effect vari nonparametr time develop expect maxim em algorithm maximum penal likelihood estim model paramet nonparametr compon byproduct em algorithm smooth paramet estim use modifi linear mix effect model faster altern method restrict maximum likelihood approach final perform propos approach evalu extens simul studi well applic data set acquir immun defici syndrom studi | D000465 | T170 |
34,661,486 | spatial distribut bat shelter livestock rabi southern brazil studi focus epidemiolog character spatial distribut bat shelter concern livestock anim rabi paran state southern brazil spatiotempor cluster analysi perform base rabi posit case desmodus rotundus shelter total suspect rabi case submit diagnosi analyz posit negat direct immunofluoresc biolog test mice posit sampl bovin equin sheep bubalin bat region unit agricultur health northeast central unit highest recurr rate posit case paran state continu endem livestock rabi highest caseload seen southern central region associ highest number vampir bat shelter natur geograph characterist favor bat hous decreas number rabi case livestock spatiotempor analys point process map control rotundus shelter suspect livestock rabi case studi area steadi statist correl howev bat may travel km prey cattl cluster bat shelter locat may sensit measur exposur furthermor futur studi consid landscap featur altitud potenti associ risk factor rabi vaccin livestock bat hematophag shelter identif combin bat control recommend increas efficaci prevent measur particular natur geograph characterist favor local bat hous | D002418;D002685;D006734;D011818;D011820;D012376;D012757 | T015;T047;T005 |
34,661,485 | heurist algorithm medic staff schedul problem multiskil vacat control main issu relat duti schedul alloc medic staff medic depart consid personnel skill person vocat prefer howev effect use staff multiskil characterist execut vocat control well investig | D000066506;D010561 | T170;T057 |
34,661,482 | function consequ poor binaur hear develop evid children unilater hear loss children receiv bilater cochlear implant poor binaur hear children hypothes contribut relat cognit academ deficit children unilater hear normal hear one ear access binaur cue cognit academ deficit could uniqu children receiv bilater cochlear implant cis young age poor access spectral cue impair binaur sensit group risk vestibularbal deficit could contribut memori learn challeng eighti eight children male femal age year group unilater hear loss n bilater ci n typic develop n complet batteri sensori cognit academ test analys reveal children hear loss group signific poorer skill account age test normal hear peer children unilater hear loss asymmetr speech percept children bilater cis p balanc languag deficit p p princip compon analys reveal deficit main cluster visuospati memori oral languag mathemat read measur explain data variabl remain compon reveal cluster self report hear balanc vestibular function speech percept deficit find indic signific development impact poor binaur hear children | D019929;D003054;D003638;D046088 | T047;T184;T074;T061;T033 |
34,661,481 | sexual harass academi har grow labor movement higher educ address sexual harass graduat worker higher educ immun epidem sexual harass unit state particular sexual harass graduat worker due larg power differenti status incom academia reli low wage work literatur show sexual harass preval across disciplin current work address problem account graduat worker precar graduat labor movement address precar begin tackl sexual harass review labor anti gender base violenc movement higher educ come togeth prevent sexual harass present recommend structur chang academia | D000074386;D017406 | T033;T048;T054 |
34,661,479 | corneal stabil visual acuiti year corneal cross link assess use abcd keratoconus stage system assess corneal stabil correct distanc visual acuiti cdva month follow corneal cross link cxl use abcd keratoconus stage system | D007640;D010778 | T047;T061 |
34,661,478 | topographi guid versus wavefront optim lasik myopia without astigmat meta analysi evalu differ efficaci predict safeti visual qualiti topographi guid custom ablat treatment tcat wavefront optim wfo laser situ keratomileusi lasik treatment myopia without astigmat | D001251;D057108;D020731;D009216 | T047;T061 |
34,661,477 | relift flap enhanc procedur primari allogen refract lenticul implant describ result relift flap enhanc procedur correct residu refract error primari lenticul intrastrom keratoplasti like | D012029;D054140 | T061;T201 |
34,661,476 | larg axi differ topograph anterior corneal astigmat manifest refract astigmat topographi guid lasik target manifest axi investig whether degre astigmat axi discrep preoper manifest refract astigmat anterior corneal astigmat impact refract visual outcom primari topographi guid laser situ keratomileusi lasik target refract astigmat provid guidanc treat eye larg axi discrep | D001251;D020731;D009216 | T047;T061 |
34,661,475 | clinic outcom femtosecond laser assist implant asymmetr icr keratoconus coincid topograph comat axe analyz clinic outcom obtain asymmetr intracorn corneal ring segment icr variabl thick width patient keratoconus identifi predict paramet final visual outcom | D007640 | T047 |
34,661,474 | comparison kane hill rbf barrett univers ii emmetropia verifi optic formula eye extrem myopia compar accuraci kane hill rbf barrett univers ii buii emmetropia verifi optic evo formula calcul intraocular len power extrem myopic eye | D007910;D009216 | T047;T074 |
34,661,473 | year result smile high myopia visual refract outcom aberr evalu year visual refract optic outcom follow small incis lenticul extract smile high myopia myopic astigmat | D003319;D009216 | T047;T023 |
34,661,472 | preoper factor affect visual acuiti follow implant diffract multifoc intraocular lens investig preoper factor affect visual acuiti implant diffract multifoc intraocular len | D007910;D000075542;D018918 | T074;T061 |
34,661,471 | accuraci total corneal power calcul multifoc toric intraocular len implant swept sourc oct base biomet vs scheimpflug tomograph evalu accuraci total corneal power calcul swept sourc optic coher tomographi base biomet rotat scheimpflug tomograph acrysof iq panoptix toric tfnt intraocular len iol alcon labroatori inc | D019654;D018918 | T061 |
34,661,469 | effect piperacillintazobactam cefepim folin dose patient receiv high dose methotrex retrospect cohort studi use japanes administr claim data delay methotrex mtx clearanc co administr piperacillintazobactam pipctaz report penicillin associ reduc mtx clearanc evid limit case describ cefepim penicillin list interact mtx aim reveal whether co administr pipctaz cfpm affect mtx clearanc use data administr databas | D010397;D010878 | T195;T109 |
34,661,468 | forens psychiatr evalu peopl charg rape croatia introduct sexual violenc substanti public health problem associ major impact victim croatia half report case sexual violenc involv rape help understand general profil consid implic aris aim research describ forens psychiatr characterist peopl charg rape method evalu peopl charg rape sent evalu largest assess centr croatia period analys n result alleg offenc often took place perpetr victim home next frequent locat street alleg victim known accus alcohol use abus present accus drink time alleg offenc alcohol relat disord present accus person histori drug use antisoci narcissist person disord present respect psychot disord rare accus found crimin respons howev forens psychiatr assess procedur inadequ consid psychosexu assess conclus intervent base around public health educ consid field forens psychiatr assess priorit improv | D011902;D012742;D019966 | T037;T033;T048;T054 |
34,661,466 | regress intraocular rosai dorfman diseas follow treatment photodynam therapi rosai dorfman diseas rdd rare form histiocytosi report caus choroid mass subsequ serous retin detach present case rdd associ choroid mass retin detach respond corticosteroid treatment regress treatment photodynam therapi pdt follow treatment patient success anatom clinic outcom recurr serous detach visual acuiti first report choroid rdd success treat pdt ophthalm surg laser imag retina | D015618;D010778;D012163 | T047;T061 |
34,661,465 | vitreomacular traction surgeri discov studi intraop oct util ellipsoid zone dynam outcom character clinic ellipsoid zone ez integr outcom surgic intervent symptomat vitreomacular traction vmt evalu util intraop optic coher tomographi oct vmt surgeri | D012164;D041623 | T047;T060 |
34,661,464 | outcom rhegmatogen retin detach repair compar surgeon continu team base practic facilit time surgeri effici use oper room time practic use team base approach patient may undergo primari rhegmatogen retin detach rrd surgeri differ surgeon instead diagnos surgeon | D012163;D066231 | T097;T047 |
34,661,463 | geospati distribut ophthalmologist older age year relat preval covid evalu coronavirus diseas covid case februari proport ophthalmologist unit state older age year provid framework success vaccin distribut ophthalmolog workforc | D000086382;D000072163;D009885 | T097;T091;T047;T067 |
34,661,462 | barrier follow retin care covid pandem survey studi character patient identifi barrier care non compliant retina appoint coronavirus diseas covid pandem | D000086382;D058873 | T047;T067 |
34,661,461 | modifi surgic techniqu submacular inject describ modifi simpl surgic techniqu submacular inject | D010959;D041623 | T116;T121;T126;T060 |
34,661,460 | predict post cataract surgeri visual acuiti vitrectom eye efficaci accuraci lambda retinometri determin abil lambda retinometri predict post cataract surgeri visual acuiti vitrectom eye | D002386;D002387 | T190;T033;T047;T061 |
34,661,459 | draw individu imag benefit recognit accuraci dees roedig mcdermott paradigm examin effect draw correct fals recognit within dees roedig mcdermott drm fals memori paradigm experi compar draw word refer use either standard black pencil colour pencil relat read control group relat read draw either black colour pencil similar boost correct recognit reduc fals recognit signal detect analys indic draw reduc amount encod memori inform critic lure increas monitor indic process contribut fals recognit reduct experi compar draw individu imag drm list item relat draw integr imag use set drm list item fals recognit lower draw individu imag relat integr imag pattern reflect decreas encod memori inform monitor therefor draw individu imag improv memori accuraci drm paradigm relat standard read control task integr draw task argu due recruit item specif process | D008568;D021641 | T041 |
34,661,458 | discord atrioventricular connect situs inversus dextrocardia doubl outlet right ventricl pulmonari stenosi anomal coronari arteri rare case report report case year old femal present cyanosi sinc birth rare cardiac anatomi viscer situs inversus dextrocardia discord atrioventricular connect doubl outlet right ventricl atrial communic subaort interventricular communic anterior leftward aorta right aortic arch singl coronari arteri branch cross right ventricl outflow tract pulmonari stenosi bilater superior vena cava correct repair atrial switch sen techniqu intracardiac baffl right ventricl outflow reconstruct success perform challeng alter anatom locat orient heart abnorm coronari arteri | D003914;D004310;D006345;D059446;D011666;D012857 | T047;T019 |
34,661,455 | advanc practic nurs activ shape nurs practic reflect advanc practic nurs activ shape nurs practic reflect abstract background develop advanc practic nurs apn role germani acut inpati set heavili depend context factor establish apn role patient care repres signific organis develop process year florenc nightingal hospit dsseldorf began implement apn role aim reflect experi develop apn role furthermor identif influenc factor understand facilit barrier intend support futur apn role develop intervent method four advanc practic nurs carri partial structur review help consolid framework implement research cfir purpos cyclic process critic self reflect accord titchen use result influenc factor summaris categori categori present support manag recognis need chang profession expertis presenc site self efficaci person characterist role clariti discuss implement apn role requir time persever organ well respect advanc practic nurs achiev role clariti process substanti boundari transfer review present context relat result howev identifi influenc factor could provid help framework futur implement process develop apn role | D057179 | T091 |
34,661,454 | ripretinib advanc gastrointestin stromal tumor plain languag summari invictus studi purpos summari help understand result invictus studi origin publish journal lancet oncolog invictus clinic studi look ripretinib potenti treatment advanc gastrointestin stromal tumor also known gist gist type cancer start digest tract also known gastrointestin tract studi particip advanc gist need fourth line greater treatment follow failur three previous treatment studi look well ripretinib work compar nonact medicin known placebo side effect particip given ripretinib dose mg day placebo result invictus studi show ripretinib increas length time particip surviv cancer got wors treatment ripretinib associ side effect vari sever result studi led ripretinib also known brand name qinlock approv usa regul medic adult advanc gist previous treat type treatment call tyrosin kinas inhibitor clinicaltrialsgov nct number nct | D005770;D046152 | T191 |
34,661,453 | popul dynam effect soil factor lamp detect system phytophthora speci associ kiwifruit diseas china china largest area kiwifruit product world pathogen associ root diseas kiwi tree investig extens research three phytophthora speci phytophthora cactorum phytophthora cinnamomi phytophthora laterali pathogen kiwi tree main plant area china studi popul densiti speci soil sampl kiwi orchard measur use multiplex real time quantit pcr base ras relat protein gene ypt p cactorum wide distribut three speci orchard zhouzhi meixian prefectur use redund analysi examin soil factor kiwi orchard understand effect popul densiti phytophthora speci redund analysi indic soil temperatur ph signific correl abund p cactorum p cinnamomi addit two loop mediat isotherm amplif detect system p cactorum develop base tiga gene color chang detect system prove accur sensit faster quantit pcr result studi along loop mediat isotherm amplif detect system great use control phytophthora diseas product kiwifruit china | D010838 | T204 |
34,661,448 | character pathogen pythium like speci associ root collar rot kiwifruit turkey period june octob widespread declin observ kiwifruit vine vineyard locat altnordu fatsa peremb district ordu provinc turkey symptom associ reddish brown rot expand root collar spars color foliag base percentag total infect sampl across vineyard common oomycet speci globisporangium intermedium phytopythium vexan globisporangium sylvaticum globisporangium heterothallicum pythium dissotocum morpholog identif isol confirm base partial dna sequenc contain nuclear rdna intern transcrib spacer region gene mitochondri cytochrom c oxidas subunit ii gene optimum growth temperatur optimum ph valu five speci rang c respect pathogen test seedl kiwifruit cv hayward reveal signific differ virul among isol phytopythium vexan globisporangium sylvaticum isol caus sever root collar rot result seedl death globisporangium heterothallicum globisporangium intermedium isol relat lower virul globisporangium spp phytopythium vexan isol signific decreas plant growth paramet plant height shoot root dri weight root length howev pythium dissotocum caus mild symptom affect paramet growth knowledg first studi report globisporangium sylvaticum globisporangium heterothallicum globisporangium intermedium caus root collar rot kiwifruit turkey also world | D029042;D011775 | T204;T002 |
34,661,446 | genom sequenc resourc causal agent persimmon anthracnos colletotrichum horii strain sd china colletotrichum horii main causal agent persimmon diospyro kaki anthracnos distribut wide persimmon produc area world report first high qualiti draft genom sequenc c horii strain sd provid refer understand adapt evolut genom structur gene popul divers among member c gloeosporioid speci complex also help understand mechan host pathogen interact improv manag strategi anthracnos | D020231;D029788 | T004;T002 |
34,661,429 | genet encod crispr compon yield effici gene edit invas pest drosophila suzukii origin asia drosophila suzukii matsumura global pest econom import soft skin fruit also common known spot wing drosophila larg control repeat applic broad spectrum insecticid resist observ field press need better understand suzukii biolog develop altern environment friend method control rna guid cas nucleas revolution function genom integr compon sever recent develop genet strategi popul control insect describ genet modifi strain encod three differ termin four differ promot express cas robust soma andor germlin suzukii cas strain rigor evalu genet cross transgen strain encod singl guid rnas target conserv x link yellow bodi white eye gene find sever casgrna strain display remark high edit capac go forward tool instrument evalu gene function suzukii may even provid tool use develop new genet strategi control invas speci | D064113 | T040 |
34,661,428 | scrambler tool de novo crispr array reconstruct applic analysi structur prokaryot popul crispr array prokaryot genom loci consist repeat sequenc altern uniqu spacer acquir foreign nucleic acid one fastest evolv part genom crispr array use differenti close relat prokaryot lineag track individu strain prokaryot communiti howev assembl full length crispr array sequenc remain problem develop scrambler tool includ sever pipelin assembl crispr array high throughput short read sequenc data assess perform model data set escherichia coli strain contain differ crispr array imit prokaryot communiti differ complex intestin microbiom extant extinct pachyderm evalu scrambler perform use model data set demonstr abil assembl crispr array correct read contain pair spacer yield precis rate recal rate check ground truth data likewis scrambler success assembl crispr array environment sampl attest match databas entri scrambler open sourc softwar githubcombiolab toolsscrambl facilit analysi composit dynam crispr array complex communiti | D064307;D012984 | T073;T170;T001;T032;T028;T090 |
34,661,427 | determin factor drive genom edit field crispr era use bibliometr past two decad discoveri crispr cas immun system repurpos effector nucleas biotechnolog tool revolution genom edit correspond work captur author repres affili countri publish paper span medicin agricultur biotechnolog use tech mine integr bibliometr network framework investig crispr literatur three time period analysi identifi semin paper lead author influenti journal rise applic topic interconnect collabor network core set foundat topic gave rise diverg avenu research applic reflect bona fide disrupt emerg technolog analysi illustr bibliometr identifi key factor deciph rise trend untangl emerg applic technolog dynam shape morph field provid insight trajectori genom edit | D015706;D064113 | T040;T062 |
34,661,426 | edit properti base editor spcas ng discard human tripronuclear zygot dna base editor compris nucleotid deaminas catalyt impair cas nickas wide use various organ effici creation point mutat provid research power tool precis genom edit howev limit scope edit discoveri engin various crispr cas system especi spcas variant xcas cas ng cas spri diversifi rang target dna sequenc expand target scope genom base edit understand edit properti comprehens conduct analysi edit properti adenin base editor cytosin base editor xcas cas ng cas spri endogen site ngn protospac adjac motif pam human genet diseas associ dna point mutat instal singl site dual site ngh pam use base editor spcas ng abemax ng anc bemax ng bes ng cultur human cell line final edit properti bes ng discard human tripronuclear embryo character studi investig edit properti dna base editor relax pam requir demonstr potenti bes ng human genet diseas relat research treatment | D064113 | T040 |
34,661,424 | pre identif confid relat eyewit lineup identif accuraci across heterogen encod condit eyewit research general fail show associ eyewit pre identif confid abil identifi perpetr lineup subsequ identif accuraci howev observ lack associ may artifact methodolog wit experienc homogen encod condit would tend restrict rang wit confid therebi effect weaken relationship subsequ identif accuraci current studi examin whether pre id confid associ subsequ lineup identif accuraci variabl encod condit across wit | D003415;D021641 | T068;T041;T054 |
34,661,423 | resili predict posttraumat cognit trauma remind task subsequ posit emot induct among veteran ptsd correct notic erratum articl report vol psycholog trauma theori research practic polici see record articl https doiorgtra supplement materi link miss titl page version articl correct object posttraumat stress disord ptsd common problem veteran resili tendenc bounc back difficult circumst negat associ posttraumat cognit ptcs among individu histori trauma may import understand respons trauma remind | D000067073;D013313;D014728 | T048;T098 |
34,661,421 | leverag multistakehold engag develop implement blueprint brief trauma focus cognit behavior therapi primari care object implement evid base treatment ebt address posttraumat stress disord ptsd public health prioriti success ebt implement requir effect collabor multipl stakehold group includ hospit leader provid patient build buy effort method describ implement scienc approach meaning stakehold engag part hybrid type effect implement trial skill train affect interperson regul ptsd treatment primari care stair pc larg safeti net hospit use primari care patient communiti advisori board cab interpret key inform interview identifi strategi adapt intervent ensur fit primari care set document stakehold engag methodolog comprehens field note minut cab meet detail focus meet suggest intervent deliveri adapt decis make process disagr adapt stakehold resolv support replic specifi operation implement strategi use across implement phase trial result key strategi involv ensur research question relev patient clinic provid b tailor intervent flexibl adapt need local set c continu engag patient provid throughout implement process build mutual respect trust credibl research team various provid group patient conclus approach engag stakehold inform implement blueprint guid implement ebt ptsd safeti net hospit primari care clinic psycinfo databas record c apa right reserv | D015928;D013313 | T048;T061 |
34,661,419 | hybrid vesicl base autolog tumor cell membran bacteri outer membran enhanc innat immun respons person tumor immunotherapi tumor heterogen often lead metastasi limit develop tumor therapi person therapi promis address tumor heterogen vesicl system design enhanc innat immun respons amplifi person immunotherapi briefli bacteri outer membran vesicl omv hybrid cell membran origin tumor mt form new function vesicl mtomv vitro experi reveal mtomv strengthen activ innat immun cell increas specif lysi abil cell homogen tumor vivo experi show mtomv effect accumul inguin lymph node inhibit lung metastasi besid mtomv evok adapt immun respons homolog tumor rather heterogen tumor revers demonstr effect person immunotherapi function inhibit tumor growth metastasi accompani good biocompat simpl prepar procedur mtomv provid great potenti clinic applic | D000080943;D007167 | T026;T061 |
34,661,416 | adsorpt characterist uranium vi aqueous solut leonardit leonardit deriv humic acid compar studi humic substanc low cost effect adsorb abund function group remedi uranium u vi contamin water research studi leonardit togeth leonardit deriv humic acid l ha use elimin u vi water divers temperatur k l ha show higher adsorpt volum u vi leonardit u adsorpt vari ph increas temperatur adsorpt kinet l ha higher determin coeffici r pseudo second order r elovich r model indic possibl chemisorpt assist adsorpt support activ energi kjmol leonardit l ha respect moreov u vi equilibrium adsorpt leonardit better depict freundlich model r suggest heterogen u vi adsorpt onto leonardit surfac howev u vi adsorpt onto l ha follow langmuir equat r impli domin role monolay adsorpt control adsorpt process thermodynam paramet includ standard entropi chang gibb free energi g suggest spontan endotherm adsorpt process addit ionic speci negat affect u vi adsorpt leonardit l ha | D006812;D014501 | T196;T109;T123 |
34,661,415 | nmr base metabolom reveal under inflammatori patholog reactiv arthriti synovi joint reactiv arthriti rea asept synov condit often develop week distant extra articular infect chlamydia salmonella shigella campylobact yersinia speci metabol chang synovi fluid sf may serv indic marker improv diagnost accuraci understand under inflammatori patholog rea aim metabol profil sf collect rea n non rea ie rheumatoid arthriti ra n osteoarthr oa n patient respect measur use nmr spectroscopi compar use orthogon partial least squar discrimin analysi opl da discriminatori metabol featur evalu diagnost potenti use receiv oper characterist roc curv analysi compar ra two alanin carnitin compar oa six nag glutam glycerol isoleucin alanin glucos metabol featur identifi diagnost biomark demonstr impact rea synov condit serum metabol profil perform correl analysi pearson rank coeffici r estim metabolit profil sf serum sampl obtain pair rea patient found signific posit metabolit r rang | D016918;D010003 | T047 |
34,661,412 | silverthioclickferropho catalyz dipolar cycloaddit tandem addit elimin reaction morita bayli hillman adduct asymmetr dipolar cycloaddit glycin imino ester morita bayli hillman mbh adduct acetyl mbh adduct describ reaction effici catalyz agoac r p thioclickferropho room temperatur afford pyrrolidin deriv bear quaternari carbon singl diastereom excel enantioselect cyclic pyrrolin ester use nucleophil instead glycin imino ester enantioselect tandem addit elimin reaction acetyl mbh adduct proceed excel yield enantioselect result format exo olefin wide substrat scope reaction transform product enabl expediti access diverg multifunction pyrrolidin optic pure fashion | D004952;D012834 | T196;T109 |
34,661,410 | evalu h triazol n n bis tert butoxycarbonyl carboxamidin solut phase resin guanidinyl sever guanidin guanidinyl peptid substanti potenti therapeut effici guanidinyl reagent vital easi access compound present pyrazol carboxamidin type reagent common use transform amin correspond guanidin report compar studi util h triazol n n bis tert butoxycarbonyl carboxamidin synthes two step readili upscal gram amount exhibit excel perform solut phase reaction rapid convert set repres aliphat primari unhind secondari amin well anilin correspond bis tert butoxycarbonyl protect guanidin enabl direct assess reactiv guanidinyl reagent convers perform deuter solvent dmf thf allow continu analysi reaction mixtur h c nmr likewis h triazol n n bis tert butoxycarbonyl carboxamidin prove versatil reagent solid phase convers exampl resin bound test peptid kffkffk fulli guanidinyl h use equival reagent per free amino group also h triazol n n bis tert butoxycarbonyl carboxamidin prove capabl complet guanidinyl steric hinder n termin residu eg n methyl amino acid peptoid resin bound peptid superior reactiv stabil demonstr heat condit make h triazol n n bis tert butoxycarbonyl carboxamidin valuabl guanidinyl reagent solut solid phase synthesi | D060327;D014230 | T052;T059;T121;T109 |
34,661,408 | theoret investig effect alkyl bromin intersystem cross bodipi base photosensit halogen alkyl bodipi deriv report suitabl candid use photosensit photodynam therapi due effici intersystem cross isc state differ spin multipl spin orbit coupl soc evalu use effect one electron spin orbit hamiltonian bromin alkyl bodipi deriv investig quantit effect alkyl bromin substitu isc bodipi deriv contain bromin atom found signific stronger soc alkyl bodipi deriv outsid frank condon region near local minima base calcul time depend densiti function theori td dft vertic excit energi soc excit state dynam three bodipi deriv explor td dft surfac hop molecular dynam employ simpl acceler approach deriv contain bromin atom found similar lifetim much shorter deriv possess alkyl moieti howev bromin atom alkyl moieti reduc homolumo gap thus assist deriv behav effici photosensit | D054879;D017319 | T121;T039;T068;T067;T070 |
34,661,407 | isoguanin hydroxyadenin aminoadenin nucleosid aza deazapurin skeleton synthesi function fluoresc clickabl side chain impact substitu physic properti function aza deaza deoxyisoguanin aza deaza aminoadenin deoxyribonucleosid decor fluoresc pyren benzofuran sensor tag clickabl side chain termin tripl bond synthes aza deaza iodo amino deoxyadenosin use central intermedi access improv two step glycosylationamin protocol function posit perform either aza deaza iodo amino deoxyadenosin follow select deamin amino group iodin aza deaza deoxyisoguanosin sonogashira suzuki miyaura cross coupl reaction employ purpos octadiynyl side chain select linker click reaction azido pyren k taut valu calcul h odioxan mixtur reveal side chain signific influenc tautomer equilibrium photophys properti fluoresc solvatochrom quantum yield new aza deazapurin nucleosid fluoresc side chain determin remark strong excim fluoresc h observ pyren dye conjug aza deazaisoguanin aminoadenin nucleosid long linker solvent includ methanol excim fluoresc neglig aminoadenin isoguanin nucleosid aza deazapurin skeleton expand class nucleosid applic fluoresc detect respect diagnost therapeut purpos | D009705;D009841 | T121;T114 |
34,661,405 | activ control solid phase microextract hierarch organ block copolym nanopor electrod array sensor charg select detect bacteri metabolit pseudomona aeruginosa produc number phenazin metabolit includ pyocyanin pyo phenazin carboxamid pcn phenazin carboxyl acid pca among pyo wide studi biomark p aeruginosa infect howev despit broad spectrum antibiot properti role precursor biosynthet rout lead secondari phenazin pca attract less attent partial due relat low concentr interfer high abund phenazin challeng address construct hierarch organ nanostructur consist ph respons block copolym bcp membran nanopor electrod array nea fill gold nanoparticl aunp separ detect pca bacteri environ bcp nea strategi design adjust ph bacteri medium p k pca p k pyo pcn ensur pca negat charg select transport across bcp membran ph pca transport aunp fill nea pyo pcn block structur character illustr rigor spatial segreg aunp nea nanopor volum allow pca secret p aeruginosa quantit determin function incub time use squar wave voltammetri surfac enhanc raman spectroscopi strategi propos studi extend chang natur hydrophil block subsequ appli detect redox activ metabolit low concentr complex biolog sampl thus help understand metabol microbi communiti | D053768;D058608 | T082;T073 |
34,661,404 | develop trifluoro h indol yl quinolin carboxamid potent select oral avail inhibitor human androgen receptor target bind function treatment castrat resist prostat cancer prostat cancer pca patient undergo androgen depriv therapi almost invari develop castrat resist prostat cancer crpc target androgen receptor ar bind function bf site offer promis option treat crpc howev bf inhibitor limit poor potenc inadequ metabol stabil extens medicin chemistri molecular model biochemistri identifi trifluoro h indol yl quinolin carboxamid vpc potent ar bf antagonist mark improv pharmacokinet properti demonstr vpc suppress ar mediat transcript chromatin bind recruit coregulatori protein novel ar antagonist select reduc growth androgen depend enzalutamid resist pca cell line demonstr vitro efficaci develop oral bioavail prodrug reduc psa product tumor volum anim model crpc observ toxic vpc potent select oral bioavail antiandrogen distinct mode action potenti novel crpc therapeut | D000076722 | T091;T062 |
34,661,402 | easi access allyl sulfon transit metal free hydrosulfonyl allen brnsted acid mediat addit hetero aryl cyclo alkyl sodium sulfin n allenyl deriv proceed water describ smooth condit reaction provid practic effici protocol regio stereoselect synthesi allyl sulfon atom step econom fashion | D000466;D028561 | T196;T109 |
34,661,401 | select synthesi divers spiro oxindol fluoren deriv via dabco promot annul reaction bindon methyleneoxindol dabco promot annul reaction bindon biindenyliden trion methyleneoxindol show interest molecular divers differ reaction condit base promot annul reaction bindon phenacylideneoxindol dcm room temperatur afford spiro indeno fluoren indolin deriv good yield high diastereoselect howev similar reaction oxoindolin yliden acet result z e isomer spiro indeno fluoren indolin diastereomer ratio hand dabco promot annul reaction bindon methyleneoxindol acetonitril differ temperatur select gave spiro benzo pentaleno b naphthalen indolin deriv complex dispiro indolin b ethanoindeno fluoren indolin satisfactori yield | D013141 | T109 |
34,661,396 | decellular extracellular matrix composit hydrogel bioink develop bioprint head neck vitro tumor model reinforc extracellular matrix ecm base hydrogel recapitul sever mechan biochem featur found tumor microenviron tme vivo gel retain sever critic structur bioactiv molecul promot cell matrix interact mechan properti tend toward viscous regim limit abil retain order structur characterist consid architectur scaffold overcom limit characterist pure ecm hydrogel present composit materi contain algin seawe deriv polysaccharid gelatin denatur collagen rheolog modifi impart mechan integr biolog activ decellular ecm decm optim process reinforc gel propos mechan stabl bioprint stiff within expect physiolog valu hydrogel elast modulus signific differ compar tumor induc preclin xenograft head neck squamous cell carcinoma hnscc mous model bioprint cell laden model high reproduc allow prolifer reorgan hnscc cell maintain cell viabil period near week cell encapsul bioink produc spheroid least cross section area day cultur posit cytokeratin immunofluoresc quantif common marker hnscc model valid model use vitro model system evalu standard care small molecul therapeut use treat hnscc clinic report fold increas ic cisplatin fold increas fluorouracil compar monolay cultur work suggest fabric vitro model use reinforc decm provid physiolog relev system evalu malign neoplast phenomena vitro due physic biolog featur replic sourc tissu microenviron | D062028 | T063 |
34,661,395 | stabl zr base metal organ framework nanopor membran effici desalin hypersalin water treatment hypersalin water critic environment challeng pervapor pv desalin promis techniqu address challeng current pv membran still suffer challeng issu low flux insuffici stabil herein propos situ nanoseed follow secondari growth strategi fabric high qualiti stabl metal organ framework mof thin membran uio high perform pervapor desalin hypersalin water address issu membran qualiti tio nano interlay introduc coars mullit substrat favor growth uio nanose layer well intergrown uio select membran layer thick low final produc via subsequ secondari growth pv separ perform hypersalin water systemat investig differ salt concentr feed temperatur long term oper differ extrem chemic environ besid near complet reject uio membran exhibit high flux lm h hypersalin water outperform current exist zeolit mof membran membran also demonstr superior long term oper stabil various harsh environ hypersalin hot acidicalkalin feed water mild foul behavior ration design propos studi applic develop high qualiti uio membran enabl harsh hypersalin water treatment also potenti extend next generat nanopor mof membran environment applic | D000073396;D058608;D018508 | T052;T082;T057;T109 |
34,661,393 | gram scalabl method synthes biscarbodiimid asymmetr monocarbodiimid platform access array phosphaguanidin amidin guanidin mild broad function group toler methodolog develop access varieti mono bis carbodiimid good yield high puriti multigram scale direct addit versatil motif facilit rapid synthesi librari novel amidinin guanidin phosphaguandin | D000578;D006146 | T109 |
34,661,391 | ultrasensit detect ribonucl acid biomark use portabl sens platform base organ electrochem transistor analysi ribonucl acid rna play import role earli diagnosi diseas great benefit patient higher cure rate howev low abund rna physiolog environ requir ultrahigh sensit detect technolog construct portabl smart phone control biosens platform base dispos organ electrochem transistor ultrasensit analysi microrna mirna biomark within h due inher amplif function devic detect mirna cancer biomark littl volum solut concentr devic distinguish blood mirna express level differ cancer stage use mous tumor model techniqu ultrasensit fast detect rna biomark high select open window mobil diagnosi various diseas low cost | D015374;D035683 | T123;T059;T114;T075 |
34,661,390 | imag dysfunct elastogenesi atherosclerosi use improv gadolinium base tetramer mri probe target tropoelastin dysfunct elastin turnov play major role progress atherosclerot plaqu failur tropoelastin cross link matur elastin lead accumul tropoelastin within grow plaqu increas instabl present gd tesma mri contrast agent specif design molecular imag tropoelastin within plaqu gd tesma tetramer probe compos tropoelastin bind peptid vvgs peptid conjug four gd iii dota monoamid chelat show relax per molecul mm mhz k ph good bind affin tropoelastin k serum half life longer h gd tesma accumul specif atherosclerot plaqu apo murin model plaqu progress h persist contrast enhanc compar monomer counterpart gd tesma tetramer gd tesma probe show clear advantag regard sensit imag time window allow better character atherosclerot plaqu | D008279 | T170;T059;T060 |
34,661,388 | print biodegrad polyurethaneurea elastom recapitul skelet muscl structur function effect skelet muscl tissu engin reli control scaffold architectur provid muscl cell requir direct togeth mechan properti match surround tissu although recent advanc print fulfil first requir avail synthet polym either rigid show unfavor surfac degrad profil latter addit natur polym general use hydrogel lack requir mechan stabil withstand forc exert muscl contract therefor one import challeng print soft elast tissu skelet muscl limit avail elast durabl biodegrad biomateri herein synthes novel biocompat biodegrad elastomer segment polyurethan polyurethaneurea tpu copolym amen print show high elast low modulus control biodegrad improv wettabl compar convent polycaprolacton pcl pcl base tpus degrad profil print tpu scaffold line potenti tissu integr scaffold replac process even though tpu attract macrophag configur print form show limit activ macrophag adhes induc muscl like structur format cc mous myoblast vitro result signific increas muscl regener vivo tibiali anterior defect rat model effect muscl regener confirm immunohistochem assess well evalu electr activ produc regener muscl emg analysi forc generat via custom made forc transduc micro ct evalu also reveal product muscl like structur case implant cell laden print scaffold result demonstr match tissu properti given applic via use tailor made polym substanti contribut regen outcom print tissu engin scaffold | D020724;D011140 | T122;T073;T109 |
34,661,387 | metal phenol network enabl lactic acid consumpt revers immunosuppress tumor microenviron sonodynam therapi nanomedicin revolution cancer therapeut strategi complet chang outcom tricki tumor evolv sophist immunosuppress tumor microenviron tme acidif metal phenol network base nanocomplex embed lactat oxidas lox mitochondri respir inhibitor atovaquon ato construct immunosuppress tme remodel sonodynam therapi sdt nanocomplex sonosensit chlorin e conjug polyphenol deriv induc generat tumor lethal reactiv oxygen speci upon ultrasound irradi lox serv catalyst intracellular lactic acid exhaust ato led mitochondri dysfunct decreas oxygen consumpt nanocomplex revers tumor immunosuppress status allevi tumor hypoxia acid tme achiev characterist enhanc sdt inhibit tumor prolifer metastasi | D059016;D014464 | T070;T061 |
34,661,386 | needl trap devic contain filter novel devic aerosol studi particl aerosol sampl contain portion total avail analyt therefor particl trap requir fulli character gaseous sampl needl trap devic ntds high use end allow sampl preconcentr free analyt well trap particl pack sorbent needl creat filter trap solid particl liquid droplet howev particl trap effici sorbent pack ntds limit especi nanoparticl address issu aerogel base electrospun polyacrylonitril pan prepar trap small particl analyz particl bound analyt pan aerogel filter fabric cut electrospun pan fiber remov remain solvent via freez dri obtain light porous fibrous structur pan aerogel heat h pan prior pack ensur stabil thermal desorpt trap effici h pan pack ntd measur use rang condit high filtrat effici obtain case mechan stabil h pan aerogel test use multipl extractiondesorpt cycl without solid sorbent particl result indic high repeat n relat standard deviat rsd develop ntd compar thin film microextract respect abil character breath sampl obtain without face mask ntd abl trap free droplet bound analyt thin film microextract abl extract free analyt fulli reflect concentr obtain two method | D005740;D009339 | T074;T104 |
34,661,385 | carbohydr sulfat mechan fine tune siglec ligand immunomodulatori famili siglec recogn sialic acid contain glycan self exploit cancer immun evas biochem natur siglec ligand remain incomplet understood emerg evid suggest import carbohydr sulfat investig specif sulfat modif affect siglec ligand overexpress eight carbohydr sulfotransferas chsts five cell line overexpress three chstschst chst chstsignific enhanc bind numer siglec unexpect two chsts galst galst diminish siglec bind suggest new mode modul siglec ligand via sulfat result cell type depend indic context sulfat glycan present import moreov pharmacolog blockad n glycan matur reveal cell type specif pattern import either class glycan product high homogen siglec cd fragment enabl mass spectrometri base bind assay determin fold fold enhanc affin neuac sulfo gal glcnac neuac gal sulfo glcnac respect neuac gal glcnac cd show signific addit affin fold disulf ligand neuac sulfo gal sulfo glcnac moreov joint overexpress chst chst cell great enhanc bind cd sever siglec final reveal chst upregul numer cancer correl poorer surviv rate sodium chlorat sensit bind siglec cancer cell line result provid new insight carbohydr sulfat general mechan tune siglec ligand cell includ cancer | D050260 | T044 |
34,661,382 | persist viabil sar cov primari infect reinfect sinc begin sar cov epidem virus isol infect patient possibl short period time strike occur constant provid guidanc clinic cours fact led confus efficaci drug initi use seem high effici viral clearanc prove ineffect modifi cours diseas immun respons also prove definit term evolut although patient mild diseas weak antibodi respons opposit true sever patient whatev antibodi respons case infect first infect general reproduc spectrum diseas similar first infect among infect larg number asymptomat symptom other moder pictur poor evolut despit dynam rapid viral clearanc laboratori test still abl generat posit result recoveri genom sequenc occur patient alreadi symptom free other still ill serious ill also good correl reason perspect year half pandem compil literatur leav us aspect anticip alway biolog case jump limit general behavior dynam infect general | D000086382;D000086402 | T047;T005;T067 |
34,661,379 | comparison f fdg petct ga fapi petct stage restag gastric adenocarcinoma studi aim evalu diagnost sensit ga fapi petct f fdg petct primari tumor nodal periton distant organ metastas primari recurr gastric adenocarcinoma gac patient lesion base comparison | D000072078 | T060 |
34,661,378 | neuro behe diseas caus nuclearfascicular forth nerv palsi neuro behe diseas nbd predilect affect parenchyma upper brainstem howev involv fourth nerv nucleus fascicl nbd previous describ report case young man acut right fourth nerv palsi histori behet diseas enhanc lesion left caudal midbrain correspond left trochlear nerv nucleusfascicl first describ case nbd produc nuclearfascicular fourth nerv palsi also demonstr import clinicoanatom correl decuss fourth nerv fiber opposit side exit midbrain | D020432 | T047 |
34,661,377 | cytolog flowcytometr find case myelomat pleural effus rare omin present multipl myeloma plasma cell myeloma hematolog malign character multifoc clonal prolifer plasma cell usual associ protein secret serum andor urin evid organ damag general present featur relat anemia bone lesion renal failur pleural effus rare multipl myeloma present often due nonmalign caus myelomat pleural effus effus direct due pleural infiltr plasma cell even rarer present case patient present dyspnea due myelomat pleural effus fluid case may subject cytolog examin protein electrophoresi flowcytometr analysi cytogenet case highlight util cytomorpholog flowcytometri diagnosi myelomat pleural effus also highlight type present portend poor prognosi patient | D005434 | T059 |
34,661,376 | inhibit parasit prolifer use ration design anti tubulin agent infecti diseas caus apicomplexan parasit remain global public health threat presenc multipl ligand bind site tubulin make protein attract target anti parasit drug discoveri howev despit remark success anti cancer agent ration develop protozoan parasit specif tubulin drug hinder lack structur biochem inform protozoan tubulin present atom structur protozoan tubulin microtubul delin architectur apicomplexan tubulin drug bind site base inform ration design parasit specif tubulin inhibitor parabulin show inhibit growth parasit display effect human cell work present first time ration design speci specif tubulin drug provid framework exploit structur differ human protozoa tubulin variant enabl develop much need novel parasit inhibitor | D000977;D010271 | T204;T121 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.